COVID-19相关ARDS患者存在两种转录组聚类:免疫特征与结局不同
该研究对COVID-19所致ARDS患者进行转录组聚类分析,识别出两种具有不同免疫特征和不同结局的特定转录组聚类。这证明了COVID-19 ARDS患者间存在异质性,可能有助于建立个体化治疗。
要点
- COVID-19相关ARDS患者可基于转录组聚类分为两种免疫特征不同的亚型。
- 不同转录组聚类对应不同临床结局,体现患者异质性。
- 该分型可能为个体化治疗策略提供依据。
核心结论
- COVID-19相关ARDS患者存在两种特定转录组聚类,免疫特征与结局不同。
主要发现
- 转录组聚类分析识别出两种免疫特征不同的COVID-19 ARDS患者聚类。
- 不同聚类对应不同结局,提示患者间存在异质性。
临床怎么用
- 可考虑基于转录组聚类对COVID-19 ARDS患者进行分型以指导个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transcriptomic clustering of patients with ARDS due to COVID-19 identified different immune profiles and outcomes. This demonstrates heterogeneity among COVID-19 ARDS patients and may help to establish personalised therapies. https://bit.ly/3h61sCj Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the respiratory illness COVID-19 (coronavirus disease 2019). The virus was first identified in December 2019 in Wuhan, China and has since then spread globally, resulting in the ongoing SARS-CoV-2 pandemic, causing more than 615 million confirmed cases of infection (https://covid19.who.int/). Although the largest proportion of SARS-CoV-2 infections in humans is characterised by a mild course of disease, about 5% to 20% of patients are hospitalised with COVID-19 due to a more severe course of disease, and require admission to the intensive care unit for diffuse lung infiltrates and severe hypoxaemia [1].
引用
- Shindo Y, Dela Cruz CS, Witzenrath M, et al. Identification of two specific transcriptomic clusters of COVID-19 acute respiratory distress syndrome patients with different immune profiles and different outcomes. Eur Respir J. 2023. PMID: 36517181. doi:10.1183/13993003.02008-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。